1. Home
  2. ACR vs ACET Comparison

ACR vs ACET Comparison

Compare ACR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$19.50

Market Cap

146.1M

Sector

Real Estate

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.22

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
ACET
Founded
2005
1947
Country
United States
United States
Employees
4
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.1M
77.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ACR
ACET
Price
$19.50
$8.22
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$24.50
$48.33
AVG Volume (30 Days)
16.3K
85.7K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.06
$0.46
52 Week High
$24.61
$9.05

Technical Indicators

Market Signals
Indicator
ACR
ACET
Relative Strength Index (RSI) 40.34 55.45
Support Level $18.83 $7.50
Resistance Level $21.27 $8.68
Average True Range (ATR) 0.66 0.54
MACD -0.30 -0.06
Stochastic Oscillator 6.52 64.64

Price Performance

Historical Comparison
ACR
ACET

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: